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Introduction 
Methods 
Conclusions 
We hypothesized that Myr-PKC βII peptide inhibitor (0.2-20 μM) would dose-
dependently attenuate fMLP induced PMN SO release.   We further  predict that  5 
to 20 μM doses would exert significant attenuation of fMLP induced PMN SO 
release compared to non-drug or low drug treated (0.2 and 0.5 μM ) PMNs and these 
effects would not be associated with a decrease in cell viability. 
Myr-PKC βII peptide inhibitor dose-dependently inhibited fMLP-induced SO 
release by about 70%; suggesting that activation of NADPH oxidase via PKC βII 
is the dominant pathway following stimulation of the leukocyte chemotactic 
receptor. This study suggests that PKC βII peptide inhibitor maybe anti-
inflammatory agent that can be used in vascular complications associated with 
I/R.  
Results 
Isolation of PMNs 
Male Sprague-Dawley rats (350–400 g, Charles River), used as PMN donors, were 
anesthetized with 2.5 % isoflurane and given a 16 ml intraperitoneal injection of 
0.5% glycogen (Sigma Chemical) dissolved in PBS. Rats were reanesthetized with 
isoflurane 16–18 h later, and the PMNs were harvested by peritoneal lavage in 30 ml 
of 0.9% NaCl, as previously described (2,3). The peritoneal lavage fluid was 
centrifuged at 200 g for 10 min at 4°C. The PMNs were then washed in 20 ml PBS 
and centrifuged at 200 g for 10 min at 4°C. Thereafter, the PMNs were 
resuspended in 2.5 ml PBS and density was calculated. The PMNs preparation were 
>90% pure and >95% viable according to microscopic analysis and exclusion of 
0.3% trypan blue, respectively.  Cell viability among all study groups was 
determined by 0.3% trypan blue exclusion. 
Measurement of SO Release From Rat PMNs 
The SO release from PMNs was measured spectrophotometrically (model 260 
Gilford, Nova Biotech; El Cajon, CA) by the reduction of ferricytochrome c (1,3). 
The PMNs (5 x106) were resuspended in 450 μl PBS and incubated with 
ferricytochrome c (100 µM, Sigma Chemical) in a total volume of 900 μl PBS in the 
presence or absence of myr PKC βII inhibitor (0.2 to 20 μM; N-myr-SLNPEWNET , 
1300 g/mol) for 15 min at 37°C in spectrophotometric cells. The PMNs were 
stimulated with 1 μM fMLP (MW= 434 g/mol) (Calbiochem) in a final reaction 
volume of 1.0 ml.  Absorbance at 550 nm was measured every 30 sec for  up to  
120sec for fMLP and the change in absorbance (SO release) from PMNs was 
determined relative to time 0. 
Statistical Analysis 
All data in the text and figures are presented as means ± S.E.M. The data were 
analyzed by analysis of variance using post hoc analysis with the Fisher’s PLSD 
test. Probability values of <0.05 are considered to be statistically significant. 
Hypothesis 
Figure 1. Schematic representation of PKC activation generating SO release in PMN. PMN 
chemotactic G-protein receptors are activated by fMLP. The G-protein subunits q and βγ 
disassociate after stimulation and activate phospholipase C beta (PLCβ) to produce inositol 1,4,5 
trisphosphate (Ins(1,4,5)P2) plus DAG  respectively from phospholipids phosphatidylinositol 4,5 
bisphosphate (PtdIns(4,5)P2). Ins(1,4,5)P2 stimulates Ca
2+ release from the endoplasmic reticulum 
(ER). Ca2+ and DAG directly activate PKC βII . Activated PKC βII phosphorylates NADPH 
oxidase to release SO (Adapted from Young et al.). 
Phosphorylation of polymorphonuclear leukocyte (PMN) NADPH oxidase by 
protein kinase C (PKC) is essential to generate superoxide (SO) release. Inhibition 
of leukocyte SO release attenuates inflammation mediated vascular tissue injury 
(e.g. myocardial ischemia/reperfusion (MI/R)).   There are 11 isoforms of PKC 
and the role of PKC isoforms that mediate this response has not been fully 
elucidated. PKC beta II (PKC βII), a classical isoform that is activated by calcium 
and diacylglycerol (DAG), following PMN chemotactic receptor stimulation with  
fMLP peptide (Fig.1) (1).  Activated PKC βII  will activate NADPH oxidase and 
stimulate SO release. Selective PKC βII peptide  inhibitor has been developed 
based on its binding sites to receptor for  C kinase (RACK) domain (Fig 2) (2). 
Myristoylation of peptides is known to be an effective strategy to enable simple 
diffusion through cell membranes to affect PKC function (3, 4).   
 
Myristoylated (Myr) PKC βII peptide inhibitor is known to inhibit PMN SO 
release at doses that correlated with restoration of post-reperfused cardiac function 
following global MI(20min)/R(45min) in leukocyte mediated cardiac MI/R 
dysfunction (1,5)  and more recently in prolonged MI(30min)/R(90min) in 
isolated rat hearts (See Poster # P 204).   However, a full dose-response  curve  
with Myr-PKC βII peptide inhibitor (0.2-20 μM) has not been  indicated 
previously. The peptide  attenuates PKC βII translocation to the cell membrane by 
inhibiting the interaction with the RACK domain (Fig.2).  Characterizing the full 
dose-response effects is essential in identifying putative mechanisms responsible 
for attenuating vascular and tissue injury following I/R. 
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Figure 2. Illustration of PKC βII peptide inhibitor. The Ca2+ binding domain for PKC βII peptide 
inhibitor (i.e., C2-4 region) is unique for PKC βII translocation to the cell membrane when 
activated (Adapted from 2) (top). PKC II peptide inhibitor mechanism of action (Adapted from 
5) (bottom) is to inhibit PKC II translocation to leukocyte substrates such as NADPH oxidase 
(Adapted from Csukai and Mochly-Rosen ). 
. 
Figure 4. fMLP (1μM)-induced peak response (120 sec) SO release in PMNs.  Myr-PKC βII peptide  inhibitor dose 
dependently (0.5-20 μM) attenuated SO release compared to untreated controls (*p<0.05; **p<0.01) by 26 ±12% 
(0.5 µM), 43 ±19% (1 µM), and 69-75 ±12% (2-20 µM). PKC βII peptide  inhibitor high dose groups (5-20 µM) 
were significantly different from the low dose group (0.2 μM) (# p<0.05). 
Figure 3. The time course response of fMLP (1μM)-induced SO release.  Myr-PKC βII peptide  inhibitor (0.5-20 
μM) dose dependently inhibited SO release from untreated controls (*p<0.05)  21-26 ±12% (0.5 μM; 30-120 sec), 
43-46 ±19% (1 μM; 30-120 sec), 58-69 ±9% (2 μM; 30-120 sec), 71-75 ±12% (5-20 μM; 30-120 sec). PKC βII 
peptide  inhibitor high dose groups (5-20 µM) were significantly different from the low dose group (0.2 μM)  
(# p<0.05) from 30-120 sec. 
 
Figure 5. . The effects of Myr-PKC βII peptide  inhibitor (0.2-20 µM) on cell viability in fMLP (1 μM)-induced SO 
release in PMNs.  Cell viability ranged between 94-96% ± 1 and was not different amongst study groups, 
suggesting that the inhibition of leukocyte SO release was not related to cell death 
 
